WebinarsNew
Deep DiveNew
Explore Business Standard
Novartis
Novartis India Ltd on Monday announced that its Board of Directors has approved the acquisition of the trademarks 'Minipress' and 'Minipres' from Pfizer Inc. USA and Pfizer Products Inc. USA for a total consideration of approximately Rs 1,250 crore. In a regulatory filing, the company said the transaction involves the acquisition of the trademarks registered in India and certain related intellectual property rights for a total aggregate consideration of Rs 1,250 crore. The company has executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc USA and Pfizer Products Inc USA, with the signing and closing of the transaction scheduled to occur simultaneously, as per the filing. The company noted that Minipress XL (containing prazosin) is primarily indicated in India for treating hypertension (high blood pressure) and managing the urinary symptoms of benign prostatic hyperplasia (BPH). The filing further highlighted that as per IQVIA MAT July 2026 data, Minipre
Pharma company Novartis India Ltd (NIL) plans to pursue disciplined, therapy-aligned acquisitions and deepen its last-mile reach into Tier 2 and Tier 3 markets to drive its next phase of growth, according to the company's annual report. The company's future strategy focuses on five anchor therapy areas: pain management, wellness, women's health, neuroscience, and transplant immunology. It aims to build new avenues for growth by protecting and extending the equity of brands such as Voveran, Calcium Sandoz, Methergin, Tegrital, Myfortic, and Simulect. Vikas Gupta, Managing Director and Chief Executive Officer, Novartis India, stated that the company is focusing on deepening its reach into non-metro markets where its specialist franchises remain under-penetrated relative to their potential. This expansion is viewed as a direct lever for volume growth. For the FY 2026-27 transition, the company is bringing established franchises, including Voveran, Methergin, Macalvit, and Calcium Sando
Drug major Novartis AG on Friday announced a strategic review of Novartis India Ltd, a public company listed on the BSE. The strategic review will include an assessment of the 70.68 per cent shareholding of Novartis AG in the company, the drug firm said in a statement. Novartis India Ltd is separate from Novartis Healthcare Pvt Ltd, the wholly owned subsidiary of Novartis group in India. Novartis Healthcare Pvt Ltd includes the Novartis Corporate Centre in Hyderabad, the commercial arm of Novartis in India, and R&D teams, which currently conduct clinical trials at more than 300 trial sites in the country. The strategic review will not impact Novartis Healthcare Pvt Ltd, Novartis AG stated. There can be no assurance that the strategic review of Novartis India Ltd will be completed in 2024, or that the outcome would result in the implementation of any transaction, it said. Novartis remains deeply committed to India with a footprint that has expanded significantly in recent years, i
JB Chemicals & Pharmaceuticals Ltd (JB Pharma)on Tuesday said it has inked a trade mark licence agreement along with promotion and distribution pact with Novartis for select ophthalmology brands entailing a total sum of Rs 1,089 crore. The board of directors at its meeting held on December 19, 2023 approved the execution of a trade mark licence agreement with Novartis Innovative Therapies AG, which is perpetual in nature for the Indian market, for a portfolio of select ophthalmology brands which will be effective in January 2027, JB Pharma said in a regulatory filing. The board also approved the promotion and distribution agreement with Novartis Healthcare Pvt Ltd for the same portfolio of select ophthalmology brands for the Indian market for a period of three years starting December 2023, it added. On the financial details of the agreements, JB Pharma said it will pay USD 116 million (Rs 964 crore), excluding applicable taxes, stamp duty and working capital, for the trade marks ..
Drug major Cipla on Monday said it has inked a licensing pact with Novartis Pharma AG to manufacture and market Galvus range, used in the treatment of type 2 diabetes, from January 1, 2026. The Mumbai-based company has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, it said in a regulatory filing. "This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category," it added. The agreement is subject to satisfaction of certain conditions precedent, the drug firm said. Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category, the drug firm stated. On Monday, shares of Cipla ended 1.02 per cent up at Rs 901.85 apiece on the BSE.